Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3500+0.1000 (+2.35%)
At close: 04:00PM EST
4.3500 0.00 (0.00%)
After hours: 07:29PM EST
Advertisement

Precision BioSciences, Inc.

302 East Pettigrew Street
Suite A-100
Durham, NC 27701
United States
919 314 5512
https://www.precisionbiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees226

Key Executives

NameTitlePayExercisedYear Born
Mr. Matthew R. KaneAdvisor733.53kN/A1977
Dr. Christopher R. HeeryConsultant587.38kN/A1980
Mr. Michael AmorosoPres, CEO & DirectorN/AN/A1978
Dr. Derek Jantz Ph.D.Co-Founder, Chief Scientific Officer & DirectorN/AN/A1976
Dr. Jefferson J. Smith Ph.D.Co-Founder & CTON/AN/AN/A
Mr. John Alexander KellyChief Financial OfficerN/AN/A1967
Mr. Shane BartonVP, Corp. Controller & Principal Accounting OfficerN/AN/A1971
Mr. Dario ScimecaGen. Counsel & Sec.N/AN/A1975
Mr. Bruce StevensVP of Quality & ComplianceN/AN/AN/A
Ms. Heather KingDirector of Marketing Communications & PRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; and iECURE to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Corporate Governance

Precision BioSciences, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement